Pretreatment with low doses of norethindrone potentiates the osteogenic effects of fluoride on human osteosarcoma cells
Open Access
- 1 October 1995
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 10 (10) , 1512-1522
Abstract
We recently reported that picomolar doses of norethindrone (NET), a synthetic analog of 19-nortestosterone, significantly stimulated human TE85 osteosarcoma cell proliferation, differentiation, and activity in vitro. In the present study, we investigated the possibility that NET interacts with another osteogenic agent, i.e., fluoride, to stimulate human TE85 osteosarcoma cell proliferation, differentiation, and activities. Bone cell proliferation was measured by the stimulation in [3H]thymidine incorporation. Differentiation was monitored by the increase in alkaline phosphatase-specific activity. Osteoblastic activity was assessed by the stimulations in collagen synthesis and in osteocalcin secretion (in the presence of 1 nM 1,25-dihydroxyvitamin D3). When the human TE85 cells were incubated with mitogenic doses of NET and fluoride concurrently, the stimulatory effects of the two agents on these parameters exhibited no significant interaction. The enhancing effect of NET on the osteogenic effect of fluoride was not due to a shift of the fluoride dose response curve. Pretreatment with NET for 24 h followed by a treatment with a mitogenic dose (i.e., 100 μM) of fluoride for an additional 24 h significantly and synergistically potentiated the effects of fluoride on the [3H]thymidine incorporation, alkaline phosphatase-specific activity, collagen synthesis, and osteocalcin secretion, compared with those with the subsequent vehicle (0.05% ethanol) treatments. In contrast, pretreatment with fluoride for 24 h before the addition of NET for 24 h did not produce significant synergistic stimulations in the test parameters. Pretreatment of TE85 cells with the same doses of dihydrotestosterone or progesterone prior to treatment with fluoride under the same conditions did not induce synergistic potentiation of fluoride in [3H]thymidine incorporation, suggesting that the synergistic interaction with fluoride is probably not a common property of anabolic sex steroids. In summary, we found that: (1) the osteogenic effects of fluoride and NET were additive when cells were treated with both agents concurrently; (2) a 24-h pretreatment with picomolar doses of NET potentiated the osteogenic actions of fluoride in human TE85 osteosarcoma cells; and (3) pretreatment with NET produced a subsequent fluoride response that was synergistic. In conclusion, these findings led us to speculate that the osteogenic actions of NET and fluoride act through different mechanisms, and that NET at low doses has a permissive effect on the osteogenic effects of fluoride, and as such NET may be used in concert with fluoride to increase osteoblast proliferation, differentiation, and activity.Keywords
This publication has 32 references indexed in Scilit:
- Picomolar norethindrone in vitro stimulates the cell proliferation and activity of a human osteosarcoma cell line and increases bone collagen synthesis without an effect on bone resorptionJournal of Bone and Mineral Research, 1994
- 1,25-dihydroxyvitamin D3 potentiates fluoride-stimulated collagen type I production in cultures of human bone marrow stromal osteoblast-like cellsJournal of Bone and Mineral Research, 1993
- Fluoride-stimulated [3H] thymidine uptake in a human osteoblastic osteosarcoma cell line is dependent on transforming growth factor βJournal of Bone and Mineral Research, 1993
- In vitro exposure to sodium fluoride does not modify activity or proliferation of human osteoblastic cells in primary culturesJournal of Bone and Mineral Research, 1993
- Journal of Bone and Mineral ResearchJournal of Bone and Mineral Research, 1990
- Sodium fluoride as an initiator of osteogenesis from embryonic mesenchyme in vitroBone, 1987
- UNCOUPLING OF BONE FORMATION AND RESORPTION BY COMBINED OESTROGEN AND PROGESTAGEN THERAPY IN POSTMENOPAUSAL OSTEOPOROSISThe Lancet, 1985
- A mouse tumor-derived osteolytic factor stimulates bone resorption by a mechanism involving local protaglandins production in boneBiochimica et Biophysica Acta (BBA) - General Subjects, 1985
- Effect of the Fluoride/Calcium Regimen on Vertebral Fracture Occurrence in Postmenopausal OsteoporosisNew England Journal of Medicine, 1982
- Effects of Different Progestogens on Lipoproteins during Postmenopausal Replacement TherapyNew England Journal of Medicine, 1981